Download Advances in pulmonary drug delivery by Philip Chi Lip Kwok, Hak-Kim Chan PDF
By Philip Chi Lip Kwok, Hak-Kim Chan
The respiration tract has been used to bring biologically lively chemical substances into the human physique for hundreds of years. notwithstanding, the lungs are advanced of their anatomy and body structure, which poses demanding situations to drug supply. Inhaled formulations are more often than not extra refined than these for oral and parenteral management. Pulmonary drug improvement is as a result a hugely really expert zone due to its many certain concerns and demanding situations. quick development is being made and gives novel recommendations to present therapy difficulties. Advances in Pulmonary Drug Delivery highlights the most recent advancements during this field.
Read or Download Advances in pulmonary drug delivery PDF
Similar pulmonary & thoracic medicine books
Written through across the world famous scientists from educational, business, and governmental sectors, Inhalation Toxicology, moment variation information the equipment and fabrics utilized in the theoretical and utilized points of inhalation toxicology. The editors emphasize the connection among the breathing method and toxicology of inhaled ingredients and view equipment and measurements for making improvements to our knowing of the elemental mechanisms of results.
Interpretation of Pulmonary functionality exams, 4th variation offers functional, clinically suitable insurance of all kinds of pulmonary functionality trying out because it applies to a number of affliction stipulations. it's aimed toward any reader with a simple wisdom of pulmonary body structure and gives an excellent foundation for administering and studying those exams.
Pulmonary movement offers physicians with a greater realizing of the constitution, functionality and pathophysiology of the pulmonary flow. It presents finished assurance from analysis and scientific review of sufferers with pulmonary high blood pressure to imaging concepts, issues and remedy.
Splendid for college kids in serious care rotations and citizens, this concise, functional guide offers the necessities of scientific and surgical serious care in an easy-to-read layout. The authors succinctly clarify the pathophysiology underlying medical issues and the main ideas of prognosis and sufferer administration, emphasizing in your price range ways.
- Cystic fibrosis
- Molecular Targeted Therapy of Lung Cancer
- Implementation of the Asthma Practice Guidelines in the Army Medical Department: Final Evaluation
- Pocket Guide to Critical Care Pharmacotherapy
Extra resources for Advances in pulmonary drug delivery
ID=244� Kamada meets primary endpoint of U�S� Phase 2 study of inhaled alpha-1 antitrypsin for the treatment of alpha-1 antitrypsin deficiency� www�kamada�com/events�php� Accessed Aug 30, 2016� Inhaled Proteins and Peptides 21 29� Sabin AB� Immunization against measles by aerosol� Reviews of Infectious Diseases 5: 514–523 (1983)� 30� Valdespino-Gomez JL, de Lourdes Garcia-Garcia M, Fernandez-de-Castro J, HenaoRestrepo AM, Bennett J, Sepulveda-Amor J� Measles aerosol vaccination� Current Topics in Microbiology and Immunology 304: 165–193 (2006)� 31� Henao-Restrepo AM, Greco M, Laurie X, John O, Aguado T� Measles aerosol vaccine project� Proceedia in Vaccinology 2: 147–150 (2010)� 32� WHO� Measles aerosol vaccine project: Report to SAGE (2012)� www�who�int/immunization/…/3_MeaslesAerosolVaccineProject-report� Accessed Jan, 2016� 33� Burger JL, Cape SP, Braun CS, McAdams DH, Best JA, Bhagwat P, Pathak P, Rebits LG, Sievers RE� Stabilizing formulations for inhalable powders of live-attenuated measles virus vaccine� Journal of Aerosol Medicine and Pulmonary Drug Delivery 21(1): 25–34 (2008)� 34� Lin WH, Griffin DE, Rotab PA, Papania M, Cape SP, Bennett D et al� Successful respiratory immunization with dry powder live-attenuated measles virus vaccine in rhesus macaques� Proceedings of the National Academy of Sciences of the United States of America 108(7): 2987–2992 (2011)� www�pnas�org/content/early/2011/01/26/1017334108�full�pdf� 35� Agarkhedkar S, Kulkarni SP, Winston S, Sievers R, Dhere RM, Gunale B, Powell K, Rota PA, Papania M� Safety and immunogenicity of dry powder measles vaccine administered by inhalation: A randomized controlled Phase I clinical trial� Vaccine 32: 6791–6797 (2014)� 36� Garrison Jr LP, Bauch CT, Bresnahan BW, Hazlet TK, Kadiyala S, Veenstra DL� Using cost-effectiveness analysis to support research and development portfolio prioritization for product innovations in measles vaccination� Journal of Infectious Diseases 204: S124–S132 (2011)� 37� Sweeney TD, Marian M, Achilles M, Bussiere J, Ruppel J, Shoenhoff M, Mrsny RJ� Biopharmaceutics of immunoglobin transport across lung epithelium� In Respiratory Drug Delivery VII, P Byron et al�, eds� Serentec Press, Raleigh, NC, pp� 59–66 (2000)� 38� Fahy JV, Cockcroft DW, Boulet LP, Wong HH, Deschesnes F, Davis EE, Ruppel J, Su JQ, Adelman DC� Effect of aerosolized anti-IgE (E25) on airway responses to inhaled allergen in asthmatic subjects� American Journal of Respiratory and Critical Care Medicine 160(3): 1023–1027 (1999)� 39� Catley MC, Coote J, Bari M, Tomlinson KL� Monoclonal antibodies for the treatment of asthma� Pharmacology & Therapeutics 132: 333–351 (2011)� 40� Moss RB, Milla C, Colombo J, Accurso F, Zeitlin PL, Clancy JP et al� Repeated aerosolized AAV-CFTR for treatment of cystic fibrosis: A randomized placebo-controlled phase 2b trial� Human Gene Therapy 18: 726–732 (2007)� 41� Zabner J, Ramsey BW, Meeker DP, Aitken ML, Balfour RP, Gibson RL et al� Repeat administration of an adenovirus vector encoding cystic fibrosis transmembrane conductance regulator to the nasal epithelium of patients with cystic fibrosis� Journal of Clinical Investigation 97: 1504–1511 (1996)� 42� Harvey BG, Leopold PL, Hackett NR, Grasso TM, Williams PM, Tucker AL et al� Airway epithelial CFTR mRNA expression in cystic fibrosis patients after repetitive administration of a recombinant adenovirus� Journal of Clinical Investigation 104: 1245–1255 (1999)� 43� Moss RB, Rodman D, Spencer LT, Aitken ML, Zeitlin PL, Waltz D et al� Repeated adeno-associated virus serotype 2 aerosol-mediated cystic fibrosis transmembrane regulator gene transfer to the lungs of patients with cystic fibrosis: A multicenter, doubleblind, placebo-controlled trial� Chest 125: 509–521 (2004)� 44� Griesenbach U, Alton EW� Expert opinion in biological therapy: Update on developments in lung gene transfer� Expert Opinion on Biological Therapy 13: 345–360 (2013)� 22 Advances in Pulmonary Drug Delivery 45� Alton EW, Boyd AC, Cheng SH, Davies JC, Davies LA, Dayan A et al� Toxicology study assessing efficacy and safety of repeated administration of lipid/DNA complexes to mouse lung� Gene Therapy 21(1): 89–95 (2014)� Accessed May, 2014� 46� DNA Science Blog: A Checklist for Gene Therapy from the UK Cystic Fibrosis Trial (2014)� http://blogs�plos�org/dnascience/2014/05/22/checklist-gene-therapy-uk-cysticfibrosis-trial/� Accessed May, 2014� 47� Densmore CL, Orson FM, Xu B, Kinsey BM, Waldrep JC, Hua P et al� Aerosol delivery of robust polyethyleneimine-DNA complexes for gene therapy and genetic immunization� Molecular Therapy 1: 180–188 (2000)� 48� Gautam A, Densmore CL, Xu B, Waldrep JC� Enhanced gene expression in mouse lung after PEI-DNA aerosol delivery� Molecular Therapy 2: 63–70 (2000)� 49� Gautam A, Densmore CL, Waldrep JC� Pulmonary cytokine responses associated with PEI-DNA aerosol gene therapy� Gene Therapy 8: 254–257 (2001)� 50� Gautam A, Densmore CL, Golunski E, Xu B, Waldrep JC� Transgene expression in mouse airway epithelium by aerosol gene therapy with PEI-DNA complexes� Molecular Therapy 3: 551–556 (2001)� 51� Densmore CL, Kleinerman ES, Gautam A, Jia S-F, Xu B, Worth LL et al� Growth suppression of established human osteosarcoma lung metastases in mice by aerosol gene therapy with PEI-p53 complexes� Cancer Gene Therapy 8: 619–627 (2001)� 52� Densmore CL� Polyethyleneimine-based gene therapy by inhalation� Expert Opinion on Biological Therapy 3: 1083–1092 (2003)� 53� FDA� Guidance for industry: Gene therapy clinical trials—Observing subjects for delayed adverse events� FDA, Rockville, MD (2006)� 54� Weers JG, Miller DP� Formulation design of dry powders for inhalation� Journal of Pharmaceutical Sciences 104(10): 3259–3288 (2015)� 55� Sakagami M� Systemic delivery of biotherapeutics through the lung: Opportunities and challenges for improved lung absorption� Therapeutic Delivery 4(12): 1511–1525 (2013)� 56� Lechuga-Ballesteros D, Miller DP� Advances in respiratory and nasal drug delivery� Molecular Pharmaceutics 12(8): 2561 (2015)� 57� Muralidharan P, Mallory E, Malapit M, Hayes Jr D, Mansour HM� Inhalable PEGylated phospholipid nanocarriers and PEGylated therapeutics for respiratory delivery as aerosolized colloidal dispersions and dry powder inhalers� Pharmaceutics 6: 333–353 (2014)� 58� DeGeorge J, Ahn CH, Andrews PA, Brower ME, Choi YS, Chun MY et al� Considerations for toxicology studies of respiratory drug products� Regulatory Toxicology and Pharmacology 25: 189–193 (1997)� 59� FDA� Draft guidance for industry and staff: Nonclinical evaluation of reformulated drug products and products intended for administration by an alternate route (2008)� http://www�fda�gov/downloads/drugs/guidancecomplianceregulatoryinform-ation/ guidances/ucm079245�pdf+&cd=1&hl=en&ct=clnk&gl=us� Accessed Jan, 2016� 60� Working PK, Newman MS, Johnson J, Cornacoff JB� Safety of poly(ethylene glycol) and poly(ethylene glycol) derivatives� In Poly(Ethylene Glycol): Chemistry and Biological Applications, Harris M, Zalipsky S, eds� Division of Polymer Chemistry Symposium, 213th National Meeting of the ACS, San Francisco, CA (April 13–17, 1997)� American Chemical Society (ACS), Washington, DC, pp� 45–57 (1998) (ACS Symposium Series, No� 680)� 61� Veronese FM, Mero A� The impact of PEGylation on biological therapies� BioDrugs 22(5): 315–329 (2008)� 62� Gursahani H, Riggs-Sauthier J, Pfeiffer J, Lechuga-Ballesteros D, Fishburn CS� Absorption of polyethylene glycol (PEG) polymers: The effect of PEG size on permeability� Journal of Pharmaceutical Sciences 98(8): 2847–2856 (2009)� 2 More Compelling than Ever Inhaled Insulin John S.
5 Increasing polyethylene glycol molecular weight increases glucose lowering action time following inhalation of 2K–5K PEGylated insulins in anesthetized dogs� (Response to sc NPH insulin in humans is shown in the dotted line�) insulin was well tolerated at inhaled doses that would support clinical investigation, whereas higher-molecular-weight PEG insulins produced some mild inflammation, which made them unsuitable for clinical development� FUTURE DIRECTIONS Although inhaled proteins and peptides have shown limited success thus far, there are a number of opportunities for future success� Appropriate situations must be assessed to determine if there is an unmet medical need that can be addressed with inhaled therapies� It seems only a matter of time before some inhaled antibodies are developed to treat some forms of local respiratory disease� Of course, the correct receptors and time action need to be addressed, and so this is not a simple endeavor� Other proteins or peptides may also be good candidates to treat local respiratory disease, such as dealing with protease–antiprotease imbalances� Modified proteins or peptides have been developed to improve pharmacokinetics for systemic delivery� In my personal opinion, pegylation provides the most promising approach for increasing systemic half-lives� It has been demonstrated that by using PEGs in the molecular weight range of 2–5 kDa, lung disappearance half-lives of the order of 7–12 h can be achieved , which is excellent for many therapies since it allows optimal once or twice a day dosing� PEGs greater than 5K tended to show a longlived component in the lung and are unlikely to be compatible with once a day dosing� Further use of inhaled proteins and peptides has definite promise� There should be careful consideration of dealing with clear unmet clinical needs and validated target selection� In addition, cost needs to be considered� Advances in protein manufacture to reduce cost will help� High-efficiency delivery systems are needed with careful consideration of aerosol properties for reproducible delivery to the lung with high deposition efficiency in the alveolar region� Excellent vibrating mesh devices for liquid delivery such as those by Aerogen and Pari should be considered� Engineered dry powder formulations advances such as those by Novartis (PulmoSphere), Civitas (ARCUS), and Pulmatrix (iSPERSE) can also aid inhaled protein development� Inhaled Proteins and Peptides 19 SUMMARY • The development of Pulmozyme and Exubera has shown that both local and systemic use of inhaled proteins can be safe and efficacious� • There are a number of opportunities for future success including inhaled antibodies, approaches to address protease–antiprotease imbalances contributing to lung disease, and PEGylated proteins and peptides to improve pharmacokinetics� • Future therapies should concentrate on unmet medical needs and validated targets� • High-efficiency delivery systems are needed with careful consideration of aerosol properties for reproducible delivery to the lung with high deposition efficiency in the alveolar region� • Cost needs to be considered� Advances in protein manufacture and biosimilars to reduce cost will help� REFERENCES 1� Depreter F, Picher C, Amighi K� Inhaled proteins: Challenges and perspectives� International Journal of Pharmaceutics 447: 251–280 (2013)� 2� Kane C, O’Neil K, Conk M, Picha K� Inhalation delivery of protein therapeutics� Inflammation & Allergy—Drug Targets 12(2): 81–87 (2013)� 3� Patton JS, Byron PR� Inhaling medicines: Delivering drugs to the body through the lungs� Nature Reviews—Drug Discovery 6: 67–74 (2007)� 4� Wolff RK� Safety of inhaled proteins for therapeutic use� Journal of Aerosol Medicine 11(4): 197–219 (1998)� http://online�liebertpub�com/doi/abs/10�1089/ jam�1998�11�197� 5� McElroy MC, Kirton C, Gliddon D, Wolff RK� Inhaled biopharmaceutical drug development: Non-clinical considerations and case studies� Inhalation Toxicology 5(4): 219–232 (2013)� 6� Siekmeier R, Scheuch S� Systemic treatment by inhalation of macromolecules— Principles, problems and examples� Journal of Physiology and Pharmacology 59(Suppl� 6): 53–79 (2008)� 7� Ponce R, Abad L, Amaravadi L, Gelzleichter T, Gore E, Green J et al� Immunogenicity of biologically-derived therapeutics: Assessment and interpretation of nonclinical safety studies� Regulatory Toxicology and Pharmacology 54: 164–182 (2009)� 8� ICH S6 (R1)� Preclinical safety evaluation of biotechnology-derived pharmaceuticals (2011)� http://www�ich�org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Safety/ S6_R1/Step4/S6_R1_Guideline�pdf� Accessed Jan, 2016� 9� Cavagnaro J� The principles of the ICH S6 and the case-by-case approach� In Preclinical Safety Evaluation of Biopharmaceuticals: A Science-Based Approach to Facilitating Clinical Trials, Cavagnaro J, ed� John Wiley & Sons, Hoboken, NJ, pp� 45–65 (2008)� 10� Clarke J, Hurst C, Martin P, Vahle J, Ponce R, Mounho B, Heidel S, Andrews L, Reynolds T, Cavagnaro J� Duration of chronic toxicity studies for biotechnologyderived pharmaceuticals: Is 6 months still appropriate?
1 Examples of siRNA-Based Therapeutics in Clinical Trials for Lung Diseases Product Name ALN-RSV01 Excellair™ Delivery Agent/ Route of Administration Naked siRNA/ intranasal Unknown/inhalation Latest Development Status Indication Sponsor RSV infection Alnylam pharmaceuticals Zabecor pharmaceuticals Asthma IIb (completed) II BARRIERS TO siRNA DELIVERY TO THE LUNG As illustrated in Figure 3�1, there are generally five steps that siRNA go through when administered via pulmonary route� Although local delivery of siRNA could obviate the need for targeting and the interaction with serum nuclease to minimize degradation, the lung itself possesses some intrinsic anatomic, physiologic, immunologic, and metabolic hurdles for efficient siRNA delivery� The specific barriers to lung 1.